Trial Design: Open label, phase II trial that aims to evaluate the efficacy and safety of adding paricalcitol to paclitaxel protein bound cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Participants will initially receive paclitaxel protein bound cisplatin and gemcitabine until disease progression at which point paricalcitol will be introduced to the chemotherapy regimen until further disease progression. Following that patients will enter a follow up phase for disease and survival status. Participants will undergo tumour biopsies before prior to and on paricalcitol plus chemotherapy treatment. PINBALL is associated with an extensive translational program.
Chief Investigator: Dr Sarah Slater
Trial contact: firstname.lastname@example.org
Clinical Trials.gov: -
Sponsor: Barts Health NHS Trust
Participating countries: UK
Source of funding: Stand Up To Cancer/CRUK/Lustgarten Foundation (Ref: SU2C-AACR-D7-20-16)